Open-access The 2025 FDA Small-Molecule Portfolio: Clinical Applications, Synthetic Approaches, Challenges, and Solutions

Abstract

In 2025, the U.S. Food and Drug Administration (FDA) approved 46 new drugs comprising 31 small-molecule entities. These approvals represent significant milestones in the evolution of privileged structures and novel mechanisms of action, serving as invaluable leads for the development of next-generation therapeutics with enhanced efficacy. This article reviews the synthetic routes and clinical indications of these newly marketed drugs, highlighting their significance in the current pharmaceutical landscape.

Keywords:
new drugs; chemical synthesis; clinical applications


location_on
Sociedade Brasileira de Química Instituto de Química - UNICAMP, Caixa Postal 6154, 13083-970 Campinas SP - Brazil, Tel./FAX.: +55 19 3521-3151 - São Paulo - SP - Brazil
E-mail: office@jbcs.sbq.org.br
rss_feed Acompanhe os números deste periódico no seu leitor de RSS
Ir para o topo Reportar erro